The long-term impact of COVID-19 on transplant recipients remains unknown. We describe the case of a 30-year-old male kidney transplant recipient from Wuhan, China that was treated for severe COVID-19 in February 2020. He suffered an acute lung and renal injury and required systemic treatment including adjustment of his immunosuppressant regime. He was followed up to 1-year after discharge. No chronic lung fibrosis or deterioration of his pulmonary function was observed. Despite COVID-19 mediated damage to his renal tubular cells, no transplant rejection occurred. His immunological profile demonstrated both cellular anti-SARS-CoV-2 reactivity and specific humoral immunity, indicating that it is beneficial for the transplanted patients to be immunized with SARS-CoV-2 virus vaccine. This case will help guide clinical decision making for immunocompromised individuals that become infected with SARS-CoV-2.
【저자키워드】 COVID-19, Immunity, Lung injury, living kidney transplant, renal tubular injury, 【초록키워드】 Treatment, Vaccine, severe COVID-19, lung, SARS-CoV-2 virus, anti-SARS-CoV-2, discharge, Humoral immunity, Deterioration, Pulmonary function, male, Patient, Lung fibrosis, kidney transplant, cellular, Injury, immunological profile, help, clinical decision, renal, recipient, rejection, renal tubular cells, immunized, Wuhan, China, occurred, required, treated, demonstrated, suffered, reactivity, immunocompromised individual, infected with SARS-CoV-2, 【제목키워드】 Transplant, clinical, Impact, report, recipient,